Responses in renal cell cancer patients in phase I clinical trials: Drug activity or spontaneous remissions? A systematic review
M. Garcia-Martin(Institut Català d'Oncologia), J. R. Germa-Lluch(Institut Català d'Oncologia), Xavier García del Muro(Institut Català d'Oncologia), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), F. Cardenal(Institut Català d'Oncologia)
Cited by 0
Related Papers
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|751
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|641